Pilot Study of Unrelated Cord Blood Transplantation
The purpose of this study is to determine the safety and feasibility of unrelated double and single cord blood transplantation in patients with haematological malignancies using reduced-intensity or myeloablative conditioning regimens.
Leukemia, Myeloid, Acute|Myelodysplastic Syndromes|Leukemia, Lymphoblastic, Acute|Lymphoma, Non-Hodgkin|Hodgkin Disease|Chronic Lymphocytic Leukemia
DRUG: Thiotepa|DRUG: Fludarabine|DRUG: Intravenous busulphan|DRUG: Thymoglobulin|DRUG: Ciclosporin|DRUG: Mycophenolate mofetil (MMF)|DRUG: Fludarabine|DRUG: Cyclophosphamide|RADIATION: Radiotherapy|DRUG: Thymoglobulin|DRUG: Ciclosporin|DRUG: Mycophenolate mofetil (MMF)|DRUG: Fludarabine|DRUG: Melphalan|DRUG: Thymoglobulin|DRUG: Ciclosporin|DRUG: Mycophenolate mofetil (MMF)
Treatment related mortality at day 100, Day 100
Disease free survival at one year post-transplant for each cohort, 1 year|Chimerism, Days 14 (myeloblative conditioning only), 28, 56, 100 and months 6 and 12|Incidence of neutrophil engraftment by day 42, Days 14, 28 and 42|Incidence of platelet engraftment by 6 months, Days 14, 28, 56, 100 and month 6|Incidence of grade II-IV and III-IV acute GVHD, Days 28, 56, 100 and months 6, 9, 12, 18 and 24|Incidence of chronic GVHD during the first year, Day 100 and months 6 and 12|One year overall survival for each treatment cohort, 1 year|Incidence of systemic infections, Twice a week pre-transplant to day 100 then weekly or as clinically indicated|Incidence of CMV, adenovirus and EBV activation, Twice a week pre-transplant to day 100 then weekly or as clinically indicated|Immune reconstitution, Days 14, 28, 56, 100 and months 6, 9, 12, 18 and 24|Dynamics of EBV infection and immunity following cord blood transplantation, Days 14, 28, 56, 100 and months 6, 9 and 12|The development (if any) of transplant associated post transplant lymphoproliferative disease (PTLD), Days 14, 28, 56, 100 and months 6, 9 and 12|Identify any possible predictive markers for patients most at risk of PTLD development, Days 14, 28, 56, 100 and months 6, 9 and 12|Quality of life, Pre-transplant and months 6, 12, 18 and 24|Incidence of one year relapse or disease progression for each treatment cohort, 1 year
The purpose of this study is to determine the safety and feasibility of unrelated double and single cord blood transplantation in patients with haematological malignancies using reduced-intensity or myeloablative conditioning regimens.